You are here

Home » Content

Basedow-Graves hastalığında cerrahi tedavi ve radyoaktif iyod tedavisinin etkinliklerinin karşılaştırılması

Comparison of the effectiveness of surgery and radioactive iodine therapy in Basedow-Graves disease

Journal Name:

  • Gülhane Tıp Dergisi

Publication Year:

  • 2008

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
The effectiveness and complications of surgery and radioactive iodine therapy, which have been two treatment modalities in Basedow-Graves disease were investigated retrospectively by comparing 24 patients who were performed thyroidectomy and 15 patients who received radioactive iodine therapy for Basedow-Graves disease between January 2004 and July 2005. Of the most commonly performed surgical procedures in the surgery group, total thyroidectomy was performed in 11 patients. I 131 treatment with a mean dose of 15.67±5.30 mCi (median 15.00) was administered in the radioactive iodine therapy group. The mean period of reaching euthyroid state after surgery was 2.33±0.97 months, whereas it was 4.28±1.54 months in the radioactive iodine therapy group (p<0.05). There was not a statistically significant difference between the two groups with respect to hypothyroidism. Radioactive iodine treatment is currently the most preferred method in the treatment of Basedow-Graves disease because of its ease of administration and cost, however it cannot be used in pregnancy and lactation, and use of it in children is under debate. Surgery is the best treatment modality in selected patients with minimal complications and recurrence risk.
Bookmark/Search this post with
Abstract (Original Language): 
Basedow-Graves hastalığının tedavi modalitelerinden olan cerrahi ve radyoaktif iyod tedavisinin etkinlikleri ve komplikasyonları, Ocak 2004 ile Temmuz 2005 tarihleri arasında Basedow-Graves hastalığı tanısı ile tiroidektomi ameliyatı yapılan 24 hasta ile radyoaktif iyod tedavisi alan 15 hasta retrospektif olarak karşılaştırılarak araştırılmıştır. Cerrahi tedavi grubunda en çok yapılan ameliyat total tiroidektomi olmuştur (11 hasta). Radyoaktif iyod tedavi grubunda ise hastalara ortalama 15.67±5.30 mCi (ortanca 15.00) dozunda I 131 uygulanmıştır. Cerrahi tedavi grubunda ameliyat sonrası ötiroid hale geliş süresi ortalama 2.33±0.97 ay olurken, radyoaktif iyod tedavi grubunda bu süre ortalama 4.28±1.54 ay olarak gerçekleşmiştir (p<0.05). Hipotiroidizm açısından her iki grup arasında istatistiksel olarak anlamlı bir farklılık tespit edilmemiştir. Radyoaktif iyod tedavisi uygulama kolaylığı ve maliyet düşüklüğü nedeniyle bugün Basedow-Graves hastalığının tedavisinde en çok tercih edilen tedavi şeklidir, fakat gebelik ve laktasyonda kullanılamaz ve çocuklarda kullanımı tartışmalıdır. Cerrahi tedavi seçilmiş vakalarda en iyi tedavi seçeneği olup, komplikasyon ve rekürrens riski az olan bir tedavidir.
FULL TEXT (PDF): 
PDF icon arastirmax-basedow-graves-hastaliginda-cerrahi-tedavi-radyoaktif-iyod-tedavisinin-etkinliklerinin-karsilastirilmasi.pdf
  • 4
241-248
  • Turkish

REFERENCES

References: 

Kaynaklar
1. Hertz S, Roberts A. Radioactive iodine in the study of
thyroid physiology. VII. The use of radioactive iodine
therapy in hyperthyroidism. JAMA 1946; 131: 81.
2. Palestini N, Grivon N, Durando R, Freddi M,
Odasso C, Robecchi A. Thyroidectomy for Graves’
hyperthyroidism. Retrospective study of patients’
appreciation. Ann Ital Chir 2007; 78: 405-412.
3. Glinoer D, Hesch D, Lagasse R, Laurberg P. The
management of hyperthyroidism due to Graves’ disease
in Europe in 1986. Results of an international survey.
Acta Endocrinol Suppl (Copenh) 1987; 285: 3-23.
4. Ku CF, Lo CY, Chan WF, Kung AW, Lam KS. Total
thyroidectomy replaces subtotal thyroidectomy as the
preferred surgical treatment for Graves’ disease. ANZ J
Surg 2005; 75: 528-531.
5. Wartofsky L, Glinoer D, Solomon B. Differences and
similarities in the diagnosis and treatment of Graves’
disease in Europe, Japan and the United States. Thyroid
1991; 1: 129-135.
6. Ljunggren J-G, Torring O, Wallin G. Quality of life aspects
and costs in treatment of Graves’ hyperthyroidism with
anti thyroid drugs, surgery, or radioiodine: results from
a prospective, randomized study. Thyroid 1998; 8:
653-659.
7. Törring O, Tallstedt L, Wallin G. Graves’
hyperthyroidism: treatment with antithyroid drugs,
surgery, or radioiodine-a prospective randomized study.
J Clin Endocrinol Metab 1996; 81: 2986-2993.
8. Roe SM. What’s new in endocrine surgery. J Am Coll
Surg 2001; 193: 202-205.
9. Ünal G. Tiroid Hastalıkları. İstanbul Üniversitesi
Cerrahpaşa Tıp Fakültesi Yayınları, 2000: 238-252.
10. Allahabadia A, Daykin J, Shippard M. Radioiodine
treatment of hyperthyroidism: prognostic factors
for outcome. J Clin Endocrinol Metab 2001; 86:
3611-3617.
11. Erem C, Algün E, Özben N ve ark. Basedow-Graves
hastalığında radyoaktif iyot tedavisinin sonuçları.
İstanbul Tıp Fakültesi Mecmuası 2000; 63: 42-47.
12. Barakate MS, Agarwal G, Reeve TS, Barraclough B,
Robinson B, Delbridge L. Total thyroidectomy is now
the preferred option for the surgical management of
Graves’ disease. ANZ J Surg 2002; 72: 321–324.
13. Witte J, Goretzki PE, Dotzenrath C, et al. Surgery for
Graves’ disease: total versus subtotal thyroidectomyresults of a prospective randomized trial. World J Surg
2000; 24: 1303-1311.
14. Lal G, Ituarte P, Kebebew E, Siperstein A, Duh OY, Clark
OH. Should total thyroidectomy become preferred
procedure for surgical treatment of Graves’ disease?
Thyroid 2005; 15: 569-574.
15. Palit TK, Miller CC III, Miltenburg DM. The efficacy of
thyroidectomy for Graves’ disease: a meta-analysis. J
Surg Res 2000; 90: 161-165.
16. Dominello A, Guinea A, Reeve TS, Robinson B, Delbridge
L. Progressive increase in thyroid function after subtotal
thyroidectomy for Graves’ disease. Asian J Surg 2000;
23: 131-135.
17. Gaujoux S, Leenhardt, Tresallet C, et al. Extensive
thyroidectomy in Graves’ disease. J Am Coll Surg 2006;
202: 868-873.
18. Werga-Kjellman P, Zedenius J, Tallstedt L. Surgical
treatment of hyperthyroidism: a ten year experience.
Thyroid 2001; 11: 187-192.
19. Chi SY, Hsei KC, Sheen-Chen SM. A prospective
randomized comparison of bilateral subtotal
thyroidectomy versus unilateral total and contralateral
subtotal thyroidectomy for Graves’ disease. World J
Surg 2005; 29: 160-163.
20. Sugino K, Minura T, Ozaki O. Preoperative change
of thyroid stimulating hormone receptor antibody
level: possible marker for predicting recurrent
hyperthyroidism in patients with Graves’ disease
after subtotal thyroidectomy. World J Surg 1996; 20:
801-806.
21. Levetan CWL. A clinical guide to the management
of Graves’ disease with radioactive iodine. Endocrine
Practice 1995; 1: 205-212.
22. Alsanea O, Clark OH. Treatment of Graves’ disease: the
advantages of surgery. Endocrinol Metab Clin North
Am 2000; 29: 321-337.
23. Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya
H. Surgical management of Graves’ disease-10-year
prospective trial at a single institution. 2008; 55:
161-167.248 • Aralık 2008 • Gülhane Tıp Derg Can ve ark.
24. Pradeep PV, Agarwal A, Baxi M, Agarwal G, Gupta SK,
Mishra SK. Safety and efficacy of surgical management
of hyperthyroidism: 15-year experience from a territary
care center in a developing country. World J Surg 2007;
31: 306-312.
25. Moreno P, Gomez JM, Gomez N, et al. Subtotal
throidectomy: a reliable method to achieve euthyroidism
in Graves’ disease. Prognostic factors. World J Surg
2006; 30: 1950-1956.
26. Weber KJ, Solorzano CC, Lee JK, Gaffud MJ, Prinz RA.
Thyroidectomy remains an effective treatment option
for Graves’ disease. Am J Surg 2006; 193: 400-405.
27. Gough I, Wilkinson D. Total thyroidectomy for
management of thyroid disease. World J Surg 2000; 24:
962-965.
28. Hermann M, Roka R, Richter B. Reoperation as
treatment of relapse after subtotal thyroidectomy in
Graves’ disease. Surgery 1999; 25: 522-528.
29. Pellegriti G, Belfiore A, Giuffrida D. Outcome of
differentiated thyroid cancer in Graves’ patients. J Clin
Endocrinol Metab 1998; 83: 2805-2809.
30. Belfiore A, Russo D, Vigneri R. Graves’ disease, thyroid
nodules and thyroid cancer. Clin Endocrinol 2001; 55:
711-718.
31. Wiersinga WM, Bartalena L. Epidemiology and
prevention of Graves’ ophthalmopathy. Thyroid 2002;
12: 855-860.
32. Kobe C, Weber I, Eschner W, et al. Graves’ disease and
radioiodine therapy. Is success of ablation dependent on
the choice of thyreostatic medication? Nuklearmedizin
2008; 47: 153-156.
33. Yin X, Latif R, Bahn R, Tomer Y, Davies TF. Influnce
of the TSH receptor gene on susceptibility to Graves’
disease and Graves' ophthalmopathy. Thyroid 2008;
16; 1048-1051.
34. Antonelli A, Fallahi P, Tolari S, Ferrai SM, Ferrannini E.
Thyroid-associated ophthalmopathy and TSH receptor
antiboides in nonmetastatic thyroid cancer after total
thyroidectomy. Am J Med Sci 2008; 336: 288-290.
35. El-Kaissi S, Frauman AG, Wall JR. Thyroid-associated
ophthalmopathy: a practical guide to classification,
natural history and management. Int Med J 2004; 34:
482–491.

Thank you for copying data from http://www.arastirmax.com